A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Clinical trial NCT01243762 · TERMINATED

Trial details

NCT number: NCT01243762
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasms Malignant

Start date: 2010-11-22
Primary completion: 2012-12-04
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.